Outcomes

The clinical evidence for Melanotan II outcomes is extremely limited, with most findings derived from case reports, animal studies, and one ongoing clinical trial. The strength of evidence is weak overall.

Skin Pigmentation Effects

One Phase 2 clinical trial is currently recruiting participants to evaluate Melanotan II as an adjunct to narrowband UV-B phototherapy for repigmentation in stable nonsegmental vitiligo (NCT07437560). However, no results from controlled human trials are yet available in the published literature.

Safety Concerns

Case reports have documented concerning adverse effects:

Oral mucosal changes: A 2026 case report describes oral mucosa changes associated with Melanotan II injections, though specific details of these changes are not provided in the available evidence
Potential malignancy risk: A 2025 case report suggests Melanotan II nasal spray may be a possible risk factor for oral mucosal malignant melanoma, though this represents only case-level evidence

Preclinical Findings

Animal studies have reported some behavioral effects:

Mood effects: A 2024 study in male rats found antidepressant-like and anti-stress effects when Melanotan II was used alongside Semax in a chronic unpredictable stress model
Metabolic effects: Animal studies from 2024 suggest involvement in metabolic signaling pathways, particularly in feeding regulation

Evidence Limitations

The current evidence base is severely limited by:

Lack of published results from controlled human trials
Reliance on isolated case reports for safety data
Most research conducted in animal models rather than humans
Absence of systematic safety or efficacy data

Disclaimer: This information is for educational purposes only and should not be considered medical advice. Consult healthcare providers before considering any treatment options.

Melanotan II

Member access required